证券代码：688117 证券简称：圣诺生物 公告编号：2026-003 成都圣诺生物科技股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以成都圣诺生物 科技股份有限公司（以下简称"公司"）2025年年度报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：人民币元 ■ 3、影响经营业绩的主要因素 报告期内，公司持续专注于主营业务多肽药物CDMO、原料药和制剂的协同发展，得益于全球多肽药物 市场降糖、减重领域的药品需求持续放量，使得公司GLP-1原料药销量大增，经营业绩大幅提升。 （二）上表中有关项目增减变动幅度达30%以上的主要原因 注：1.本报告期初数同法定披露的上年年末数。 2.表中财务数据及指标均以合并报表数据填列，但未经审计，最终结果以公司2025年年度报告为准；表 中增减变动幅度数据如有尾差，系四舍五入所致。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状 ...

嘉宾： 刘金山：著名演员 孟化：中日友好医院普外科代谢减重中心主任 主任医师 张念荣：中日友好医院普外科代谢减重中心 副主任医师 林熙明：中日友好医院普外科代谢减重中心 中医医师 张诗岩：中日友好医院普外科代谢减重中心 运动康复师 关键词：烙饼卷带鱼 减重 潘大庆 脂肪肝 闲人马大姐 著名演员刘金山是荧幕上的 "老吃家"，最深入人心的作品都与吃相关，也曾因为角色需要真的增肥几 十斤。年已花甲的他目前仍活跃在片场，而他在戏外的真实小日子里，有勾起思念的地道京味美食，对 家人实打实的关爱，也有养生控制体重的小"傲娇"和小烦恼。 而在去年成功甩掉430斤的中国第一胖宇宙，作为减重"优等生"到场，和帮助他达成这项奇迹的中日友 好医院普外科代谢减重中心孟化主任团队一起，带来吃好不吃胖的新春密码，化作农历新年最治愈的健 康祝福。 e 一道烙饼卷带鱼，是很多京味馆子里的必点菜，也是刘金山记忆里的父母味道。在私房话大起底的环节 里，刘金山道出为照顾家中几位老人而丁克21年，直到50多岁才生下女儿的感人故事；也娓娓道来曾为 了塑造角色而真吃真喝甚至增肥几十斤的戏中过往。虽是为艺术献身，却也真实的带来了体重和健康的 困扰。 体重 ...

Core Viewpoint - The article emphasizes the importance of a comprehensive approach to weight loss, highlighting that medication alone, such as semaglutide, is insufficient without lifestyle changes and professional guidance [4]. Group 1: Medication and Professional Guidance - The introduction of semaglutide in medical institutions has led to an increase in consultations at weight loss and endocrinology clinics [4] - It is recommended that patients seeking weight loss consult qualified medical professionals for proper assessment and diagnosis to create a scientific weight loss plan [4] - The use of weight loss medications requires standardized management, and reliance solely on medication is unlikely to yield effective results [4] Group 2: Dietary Recommendations During Medication - Maintaining a balanced diet is crucial while taking semaglutide, with recommendations to reduce refined carbohydrates and sugary drinks, and to limit salt intake to 5 grams per day [6] - During dinner, it is advised to avoid greasy and sweet foods, opting for light and easily digestible options to prevent gastrointestinal discomfort [6] Group 3: Foods to Avoid - High-fat foods, such as fried items and heavily cooked dishes, should be avoided as they can cause gastrointestinal discomfort, especially when taking semaglutide [7] - Foods high in trans fats and saturated fats, including full-fat dairy products and red meats, can exacerbate gastrointestinal issues and affect medication efficacy [7] - High-sugar foods, including sauces, baked goods, and sugary drinks, should be strictly controlled to prevent blood sugar fluctuations, particularly for diabetic patients [7] - High-sodium foods, such as chips and pickled products, can increase blood pressure and pose risks for heart disease, especially in type 2 diabetes patients [9] - Refined carbohydrates and high-sugar starchy vegetables should be minimized, with a preference for whole grains and low-sugar vegetables to better align with semaglutide's effects [9] - Alcohol should be reduced or avoided as it can aggravate digestive issues and increase the risk of hypoglycemia while on semaglutide [10]

减重的关键是控制能量的收支平衡，只有能量摄入小于能量支出才能减重。只吃水煮菜，但如果吃得特 别多，还吃很多能量比较高的菜，比如土豆片、山药片、藕片等淀粉含量高的蔬菜，也会长胖。而且， 只吃水煮菜，不吃肉蛋奶、水果等食物，不能摄入身体所需的全部营养素，比如优质蛋白质、脂肪等， 可能会导致营养不良，影响身体健康。 （来源：劳动午报） 转自：劳动午报 ...

成都市第三人民医院减重门诊，医生在为患者做检查。 想减重的患者在成都市第三人民医院做运动治疗。 成都市第三人民医院肥胖及代谢性疾病中心已累计完成6835台减重手术。 在减重门诊，你会听到关于自我重塑的千百种讲述。 从减肥训练营里瘦下来后又成倍反弹的患者，在长久崩溃后，第一次想从科学角度知道自己身体失控的 根源；产后两年内长胖了100多斤的妈妈，谈到由肥胖引起的多种代谢性疾病就开始大哭；低着头一句 话不说的孩子，埋头仓皇逃避着和别人的眼神接触；当然，还有穿着大码T恤的年轻人、体型纤细但有 脂肪肝的女生、挺着啤酒肚的中年男士…… "减重是一场漫长战役。"杨华武是成都市第三人民医院肥胖及代谢性疾病中心的医生，在这个国内较早 开设的减重门诊里，年轻的他见过太多即使面对体重反复，依然坚持重新掌控自我的韧劲。因此，他总 说很佩服那些减重成功的患者。 眼下，随着为期3年的"体重管理年"活动开展，这里也发生着更多改变。 "增加的门诊量中，接近40%是超重患者，他们刚胖起来就主动积极来减重，不再是因胖致病后才治 疗。"杨华武和同事欣喜于这种趋势。在他们看来，比减重更重要的是回到健康的生活状态，并在这个 过程中唤醒自我健康的主体 ...

Core Viewpoint - The company, Jiangsu Hengrui Medicine Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HRS-7535, a novel oral small molecule GLP-1 receptor agonist aimed at treating type 2 diabetes and weight loss [1] Group 1: Product Development - HRS-7535 is designed to activate GLP-1 receptors, promoting insulin secretion from the pancreas, reducing glucagon secretion, and suppressing gastric emptying [1] - The drug also enhances satiety and suppresses appetite through central mechanisms, leading to reduced energy intake [1] - There are currently no oral small molecule GLP-1 receptor agonists available in the global market [1] Group 2: Financial Investment - The cumulative research and development investment for HRS-7535 has reached approximately 369.4 million yuan [1]

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of HRS-7535 tablets, which will commence shortly [1] Group 1: Product Information - HRS-7535 tablets are a novel oral small molecule GLP-1 receptor agonist designed to treat type 2 diabetes (T2DM) and aid in weight loss [1] - The mechanism of HRS-7535 includes activating GLP-1 receptors to promote insulin secretion from the pancreas, reduce glucagon secretion, and inhibit gastric emptying [1] - Additionally, HRS-7535 influences the central nervous system to enhance satiety and suppress appetite, leading to a direct reduction in energy intake [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-7535 tablets, a new oral small molecule GLP-1 receptor agonist aimed at treating type 2 diabetes and weight loss [1]. Group 1: Product Development - The clinical trial approval for HRS-7535 tablets will allow the company to initiate trials in the near future [1]. - HRS-7535 functions by activating GLP-1 receptors, which promotes insulin secretion from the pancreas, reduces glucagon secretion, and inhibits gastric emptying [1]. - The drug also enhances satiety and suppresses appetite through central mechanisms, leading to reduced energy intake [1]. Group 2: Market Implications - The introduction of HRS-7535 could provide a new treatment option for type 2 diabetes (T2DM) patients, addressing both glycemic control and weight management [1].

Core Viewpoint - The article emphasizes the importance of sustainable weight management and highlights the challenges faced by individuals in maintaining weight loss, particularly for those with moderate to severe obesity. It discusses the shift towards surgical interventions as a preferred treatment option for obesity, as traditional methods like diet and exercise often prove ineffective for this demographic [3][5]. Group 1: Weight Management Trends - The Chinese government is promoting a "Weight Management Year" initiative to encourage healthy lifestyles, making weight loss a frequent topic of discussion [1]. - The article features a case study of Mr. Ge, who successfully reduced his weight from 297 pounds to 128 pounds through surgical intervention and lifestyle changes [3]. Group 2: Medical Insights on Obesity - Medical professionals indicate that for individuals with moderate to severe obesity, relying solely on diet and exercise for weight loss is often unsuccessful. The 2024 obesity treatment guidelines recommend prioritizing surgical options [5]. - Obesity is described as a medical condition rather than a matter of willpower, with many patients experiencing insulin resistance and related health issues that complicate weight loss efforts [5]. Group 3: Practical Weight Loss Tips - It is advised to maintain three meals a day to prevent metabolic slowdown, which can hinder weight loss efforts [6]. - Adjusting the order of food consumption—starting with soup, then vegetables and protein, followed by carbohydrates—can aid in weight management [7]. - Going to bed with a slight feeling of hunger is beneficial, as long as it is within a tolerable range, to avoid high insulin levels that can sabotage weight loss [8]. - Incorporating exercise into daily routines rather than using it as a compensatory measure for overeating is recommended, as the caloric burn from exercise is often insufficient to offset excessive food intake [8]. - Seeking professional guidance for personalized weight loss plans is encouraged, rather than attempting to lose weight independently [9].

Group 1: Pharmaceutical Sector - The innovation drug sector is expected to be the main focus, with particular attention on small nucleic acid technology and its accelerated development by 2026 [1][2] - The pharmaceutical industry is driven by supply creating demand, with significant trends observed from 2018 to 2024, including breakthroughs in PD-1, ADC technology, and new generation immunotherapy [2] - Key companies to watch in the pharmaceutical sector include Heng Rui Medicine, Hansoh Pharmaceutical, China National Pharmaceutical Group, and others involved in small nucleic acid and weight loss drug development [2] Group 2: CXO and Upstream Life Sciences - The CXO sector is expected to see continued improvement in fundamentals and valuation recovery, with a focus on companies like WuXi AppTec and Kanglong Chemical [3] - Upstream life sciences are benefiting from improved domestic research conditions, with companies like BGI Genomics and Bidu Pharmaceutical showing positive performance trends [3] - The raw material drug sector is entering a bottom price range, with companies that have quality clients and orders likely to see improved profit margins [3] Group 3: Medical Devices - The medical device sector is anticipated to benefit from improved hospital demand and inventory optimization, with a potential turning point in 2026 [4] - High-value consumables are expected to gain from collective procurement, enhancing domestic production capabilities [4] - Key players in the medical device sector include Mindray Medical, United Imaging Healthcare, and others [4] Group 4: Healthcare Consumption - The healthcare service sector is under pressure in 2025, but a mild recovery is expected in 2026, particularly in essential medical services and products [5] - Traditional Chinese medicine is projected to stabilize and grow, with a focus on OTC and prescription drug innovations [5] - The pharmacy sector is experiencing increased concentration due to regulatory changes, with companies like Yifeng Pharmacy and Dazhong Pharmacy showing improved performance [5]